Literature DB >> 11746719

Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: a microiontophoretic study in the rat locus coeruleus.

S T Szabo1, P Blier.   

Abstract

It was previously shown that the excitatory effect of the 5-HT(1A) agonist 8-OH-DPAT on firing activity of locus coeruleus (LC) norepinephrine (NE) neurons and the inhibitory action of the 5-HT(1A) antagonist WAY 100,635 are dependent on the presence of 5-HT neurons, whereas the inhibitory action of the 5-HT(2) agonist DOI is not. Using in vivo extracellular unitary recordings performed in anesthetized rats, iontophoretic applications of the excitatory amino acid antagonist kynurenate attenuated the enhancement in firing produced by glutamate and kainate. In contrast, GABA applications decreased the firing activity of NE neurons which was attenuated by the enhancement produced by glutamate and kainate. In contrast, GABA applications decreased the firing activity of NE neurons which was attenuated by the GABA(A) receptor antagonist bicuculline. 8-OH-DPAT (10-60 microg kg(-1), i.v.) produced a dose-dependent enhancement in the firing activity of NE neurons that was abolished in the presence of kynurenate application. The selective 5-HT(1A) receptor antagonist WAY 100,635 (100 microg kg(-1), i.v.) suppressed NE firing which was reversed by the selective 5-HT(2A) antagonist MDL 100,907 (200 microg kg(-1), i.v.). In the presence of bicuculline, the inhibitory effect of WAY 100,635 was blunted. These results suggest that WAY 100,635 mainly attenuates NE neuron firing by blocking inhibitory 5-HT(1A) receptors on glutamatergic neurons, thereby enhancing glutamate release and activating excitatory amino acid receptors, possibly of the kainate subtype, on 5-HT terminals. The ensuing increased 5-HT release would then act on excitatory 5-HT(2A) receptors on GABA neurons that would ultimately mediate the inhibition of NE neurons. The prevention of the excitatory action of 8-OH-DPAT on NE neuron firing by kynurenate is also consistent with this neurocircuitry. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11746719     DOI: 10.1002/syn.10009

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  23 in total

Review 1.  Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.

Authors:  Steven T Szabo; Michael J Thorpy; Geert Mayer; John H Peever; Thomas S Kilduff
Journal:  Sleep Med Rev       Date:  2018-11-08       Impact factor: 11.609

2.  Examining the underpinnings of loudness dependence of auditory evoked potentials with positron emission tomography.

Authors:  Rajapillai L I Pillai; Elizabeth A Bartlett; Mala R Ananth; Chencan Zhu; Jie Yang; Greg Hajcak; Ramin V Parsey; Christine DeLorenzo
Journal:  Neuroimage       Date:  2020-03-10       Impact factor: 6.556

3.  Neurologic bases for comorbidity of balance disorders, anxiety disorders and migraine: neurotherapeutic implications.

Authors:  Carey D Balaban; Rolf G Jacob; Joseph M Furman
Journal:  Expert Rev Neurother       Date:  2011-03       Impact factor: 4.618

4.  Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission.

Authors:  Olga Chernoloz; Mostafa El Mansari; Pierre Blier
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

5.  Predator stress engages corticotropin-releasing factor and opioid systems to alter the operating mode of locus coeruleus norepinephrine neurons.

Authors:  Andre L Curtis; Steven C Leiser; Kevin Snyder; Rita J Valentino
Journal:  Neuropharmacology       Date:  2011-12-23       Impact factor: 5.250

6.  Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice.

Authors:  Hai T Nguyen; Bruno P Guiard; Alexandre Bacq; Denis J David; Indira David; Gaël Quesseveur; Sophie Gautron; Connie Sanchez; Alain M Gardier
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

7.  Knockout of the norepinephrine transporter and pharmacologically diverse antidepressants prevent behavioral and brain neurotrophin alterations in two chronic stress models of depression.

Authors:  Britta Haenisch; Andras Bilkei-Gorzo; Marc G Caron; Heinz Bönisch
Journal:  J Neurochem       Date:  2009-08-18       Impact factor: 5.372

8.  Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors.

Authors:  Roberto William Invernizzi; Giuseppina Sacchetti; Stefania Parini; Sabrina Acconcia; Rosario Samanin
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

9.  Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion.

Authors:  Tommaso Cassano; Silvana Gaetani; Maria Grazia Morgese; Teresa Macheda; Leonardo Laconca; Pasqua Dipasquale; Juan Taltavull; Toni S Shippenberg; Vincenzo Cuomo; Gabriella Gobbi
Journal:  Neurochem Res       Date:  2009-02-20       Impact factor: 3.996

10.  Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder.

Authors:  Olga Chernoloz; Mostafa El Mansari; Pierre Blier
Journal:  Psychopharmacology (Berl)       Date:  2009-07-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.